Trial reportInvestigative ophthalmology & visual science2010
Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.
Trial report in Investigative ophthalmology & visual science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00306488 (A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration), which is not on this map. Cited by 55 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
Who cites it
55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.The Cochrane database of systematic reviews · 2023Pooled it
- Progression of Unifocal versus Multifocal Geographic Atrophy in Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.Ophthalmology. Retina · 2020Pooled it
- Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.The Cochrane database of systematic reviews · 2017Pooled it
- Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.The Cochrane database of systematic reviews · 2017Pooled it
- Local Progression Kinetics of Geographic Atrophy Depends Upon the Border Location.Investigative ophthalmology & visual science · 2021Trial
- Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.Investigative ophthalmology & visual science · 2013Trial
- Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry.Investigative ophthalmology & visual science · 2011Trial
- Natural History of Macular Sensitivity in Best Vitelliform Macular Dystrophy: Microperimetry-Derived Outcome Measures in Preparation For Clinical Trials.Investigative ophthalmology & visual science · 2026Article
- A gel-forming antioxidant eye drop for photoreceptor protection in retinitis pigmentosa.Drug delivery and translational research · 2026Article
- Tetrahedral DNA Framework Penetrating Ocular Barrier for Treatment of Retinal Oxidative Stress.ACS omega · 2025Article
- Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration.Drug delivery and translational research · 2025Review
- Different Therapeutic Approaches for Dry and Wet AMD.International journal of molecular sciences · 2024Review
- Longitudinal Changes of Visual Sensitivity With Geographic Atrophy Progression Assessed by Defect-Mapping Microperimetry.Investigative ophthalmology & visual science · 2024Article
- The Cellular and Organismal Effects of Nitroxides and Nitroxide-Containing Nanoparticles.International journal of molecular sciences · 2024Review
- Visual Sensitivity Loss in Geographic Atrophy: Structure-Function Evaluation Using Defect-Mapping Microperimetry.Investigative ophthalmology & visual science · 2024Article
- Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future.Biomedicines · 2023Review
- Biomaterials used for tissue engineering of barrier-forming cell monolayers in the eye.Frontiers in bioengineering and biotechnology · 2023Review
- Effect of Esculetin onMolecules (Basel, Switzerland) · 2022Article
- Neuroprotection for Age-Related Macular Degeneration.Ophthalmology science · 2022Review
- Recent Advances in Age-Related Macular Degeneration Therapies.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
purposeTo investigate the safety and preliminary efficacy of OT-551, a disubstituted hydroxylamine with antioxidant properties, for the treatment of geographic atrophy (GA), the advanced atrophic form of age-related macular degeneration (AMD).
methodsThe study was a single-center, open-label phase II trial, enrolling 10 participants with bilateral GA. Topical 0.45% OT-551 was administered in one randomly assigned eye three times daily for 2 years. Safety measures were assessed by complete ophthalmic examination, fundus photography, and review of symptoms. The primary efficacy outcome measure was the change in best corrected visual acuity at 24 months. Secondary efficacy measures included changes in area of GA, contrast sensitivity, microperimetry measurements, and total drusen area from baseline.
resultsStudy drug was well tolerated and was associated with few adverse events. The mean change in BCVA at 2 years was +0.2 ± 13.3 letters in the study eyes and -11.3 ± 7.6 letters in fellow eyes (P = 0.0259). However, no statistically significant differences were found between the study and fellow eyes for all other secondary outcome measures.
conclusionsOT-551 was well tolerated by study participants and was not associated with any serious adverse effects. Efficacy measurements in this small study indicate a possible effect in maintaining visual acuity. However, the absence of significant effects on other outcomes measures in this study suggests that OT-551, in the current concentration and mode of delivery, may have limited or no benefit as a treatment for GA (ClinicalTrials.gov number, NCT00306488).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.